Back to results

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

Primary Purpose

Dravet Syndrome

Status

Completed

Phase

Phase 1

Locations

United States

Study Type

Interventional

Intervention

EPX-100 (Clemizole Hydrochloride)

Placebos

About this trial

This is an interventional treatment trial for Dravet Syndrome focused on measuring Clemizole

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Signed informed consent prior to any study-related procedures
Male or female subjects 18 to 50 years of age inclusive
Subject's body mass index (BMI) is ≤ 30 kg/m2
Female subjects of childbearing potential must not be pregnant or lactating with a negative serum human chorionic gonadotropin (HCG) pregnancy test result at Screening, Day -1, or Day 19.
Female subjects of childbearing potential and male subjects must use an adequate method of contraception from Screening until completion of the study. Acceptable methods of contraception are barrier methods (male condom, female condom, diaphragm, cervical cap, spermicide, or intrauterine device [IUD]), surgical sterility (documented doctor's report of vasectomy, hysterectomy, and/or bilateral oophorectomy), oral hormonal contraceptives, hormonal IUD, and/or postmenopausal status (defined as at least 1 year without menses as demonstrated by medical history or subject report).
Subject is in good health as determined by vital signs, medical history, physical exam, and safety laboratory analyses at Screening and during the study.

Exclusion Criteria:

Subject has used an investigational product within 30 days prior to enrollment or during the study.
Subject has used prescription or non-prescription drugs (including vitamins, minerals, and herbal/plant-derived preparations) within 2 weeks of enrollment (excluding oral hormonal contraceptives, hormonal IUD, hormone replacement therapy, and acetaminophen) unless deemed acceptable by the Investigator in consultation with the Sponsor.
Subject has a positive drug and/or alcohol test at Screening, Day -1, or Day 19.
Subject has a history of drug or alcohol abuse within 2 years before Screening.
Subject is unable to abstain from ingesting alcohol, caffeine, grapefruit or grapefruit juice, pomelo or pomelo juice, or Seville oranges or Seville orange juice for 72 hours prior to dosing and throughout the dosing periods.
Concurrent use of substances, including drugs, known to interfere with EPX-100, including moderate or severe inducers or inhibitors of CYP3A4 and CYP2D6.
The subject has a clinically significant history of endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major diseases or malignancy.
Subject has evidence of any of the following cardiac conduction abnormalities:
1. QTcF interval >430 msec for males and >450 msec for females
2. PR interval ⩾ 200 msec
3. Evidence of second- or third-degree atrioventricular block (AVB)
4. Electrocardiographic evidence of complete left bundle branch block (LBBB), complete right bundle branch block (RBBB), or incomplete LBBB
5. Intraventricular conduction delay with QRS duration >120 msec
6. Heart rate <40 bpm
7. Pathological Q waves (defined as >40 msec or depth >0.4-0.5 mV)
8. Evidence of ventricular pre-excitation.

Sites / Locations

TKL Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

EPX-100

Placebo

Arm Description

Single and multiple doses of 20, 40, 80mg of EPX-100 (Clemizole Hydrochloride)

Single and multiple doses of 20, 40, 80mg of placebo

Outcomes

Primary Outcome Measures

Treatment-emergent adverse events (TEAEs)

To evaluate the safety of single and multiple escalating doses of oral EPX-100 in healthy subjects.

Serial ECGs - QTcF Interval

To evaluate the safety of single and multiple escalating doses of oral EPX-100 in healthy subjects.

Physical Examinations Including Actual Body Weight

To evaluate the safety of single and multiple escalating doses of oral EPX-100 in healthy subjects.

Secondary Outcome Measures

Plasma Concentrations of EPX-100 in Fasting State

Determine the pharmacokinetic (PK) profile of single and multiples doses of 20 mg, 40 mg, and 80 mg twice daily of EPX-100.

Plasma Concentration of EPX-100 following a High-Fat Meal

Determine the PK profile of a single dose of EPX-100 in the fasting state compared with after a high-fat meal.

Full Information

NCT ID

NCT04069689

First Posted

August 22, 2019

Last Updated

June 23, 2020

Sponsor

Epygenix

1. Study Identification

Unique Protocol Identification Number

NCT04069689

Brief Title

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

Official Title

A Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to Assess Safety and Pharmacokinetics of Escalating Single and Multiple Oral Doses of EPX-100 in Fasting Healthy Subjects and Following a High-Fat Meal

Study Type

Interventional

2. Study Status

Record Verification Date

June 2020

Overall Recruitment Status

Completed

Study Start Date

August 29, 2019 (Actual)

Primary Completion Date

November 27, 2019 (Actual)

Study Completion Date

November 27, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Epygenix

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

5. Study Description

Brief Summary

This is a placebo-controlled, double-blind, 2-period study in 3 sequential groups of 8 healthy subjects each. The safety and pharmacokinetics of escalating single and multiple oral doses of EPX-100 will be assessed in fasting healthy subjects and following a high-fat meal.

Detailed Description

This is a placebo-controlled, double-blind, 2-period study in 3 sequential groups of 8 healthy subjects each. Subjects will be admitted on two occasions to the clinical research center: Day -1 for 14 days and discharged on Day 13 and then re-admitted on Day 19 for 3 days and discharged on Day 21. Subjects will fast after midnight on the day of each admission. On Day 1 of study of the low-dose group (cohort 1), subjects will be randomized to a single dose of 20 mg EPX-100 (N=6) or placebo (N=2) in the morning and then remain fasting for 4 hours after dosing. Safety will be assessed and blood samples will be obtained to calculate PK at the following time points: 0, 0.5, 1, 2, 4, 6, 8, 12, 18, and 24 hours following the first dose of EPX-100 or placebo. The subjects will remain in the study research center for daily 8 AM (± 2 hours) blood samples for 5 consecutive days (Days 3 - 7; one blood sample per day). On Days 8 - 11, subjects will be administered 20 mg EPX-100 or placebo twice daily (BID) at least one hour prior to the morning meal and at least 2 hours after the evening meal (approximately 12 hours apart). A single dose of 20 mg EPX-100 or placebo will be administered on Day 12 in the fasting state and subjects will remain fasting for 4 hours after dosing. Blood samples will be drawn at the following time points: 0, 0.5, 1, 2, 4, 6, 8, 12, 18, and 24 hours to determine multiple-dose PK. After a washout period of at least one week following the last dose of EPX-100 or placebo, subjects will return to the clinical research center on Day 19 and safety will be assessed. On Day 20, subjects will ingest a high-fat morning meal over 30 minutes; thereafter, the subject will receive a single dose of 20 mg EPX- 100 or placebo at 30 minutes after the start of the meal. Blood samples will be drawn at the following time points: 0, 0.5, 1, 2, 4, 6, 8, 12, 18, and 24 hours after the administration of study drug to determine the PK of EPX-100 in the fed state. Once the 20 mg dose level of EPX-100 is evaluated and the Safety Review Committee (SRC) determines it is safe to escalate to the next dose level, subsequent groups of 8 subjects each will be administered 40 mg (cohort 2) and 80 mg (cohort 3) (N=6 active drug, N=2 matching placebo) EPX-100 and follow the same study procedures as the low-dose group (cohort 1). Throughout the study period, subjects will undergo cardiac assessments, safety assessments, and PK sampling.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Dravet Syndrome

Keywords

Clemizole

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigator

Allocation

Randomized

Enrollment

24 (Actual)

8. Arms, Groups, and Interventions

Arm Title

EPX-100

Arm Type

Experimental

Arm Description

Single and multiple doses of 20, 40, 80mg of EPX-100 (Clemizole Hydrochloride)

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

Single and multiple doses of 20, 40, 80mg of placebo

Intervention Type

Drug

Intervention Name(s)

EPX-100 (Clemizole Hydrochloride)

Other Intervention Name(s)

Clemizole Hydrochloride, Clemizole HCL

Intervention Description

EPX-100 (Clemizole Hydrochloride)

Intervention Type

Drug

Intervention Name(s)

Placebos

Intervention Description

Placebo to match EPX-100

Primary Outcome Measure Information:

Title

Treatment-emergent adverse events (TEAEs)

Description

To evaluate the safety of single and multiple escalating doses of oral EPX-100 in healthy subjects.

Time Frame

21 days

Title

Serial ECGs - QTcF Interval

Description

To evaluate the safety of single and multiple escalating doses of oral EPX-100 in healthy subjects.

Time Frame

21 days

Title

Physical Examinations Including Actual Body Weight

Description

To evaluate the safety of single and multiple escalating doses of oral EPX-100 in healthy subjects.

Time Frame

21 days

Secondary Outcome Measure Information:

Title

Plasma Concentrations of EPX-100 in Fasting State

Description

Determine the pharmacokinetic (PK) profile of single and multiples doses of 20 mg, 40 mg, and 80 mg twice daily of EPX-100.

Time Frame

13 days

Title

Plasma Concentration of EPX-100 following a High-Fat Meal

Description

Determine the PK profile of a single dose of EPX-100 in the fasting state compared with after a high-fat meal.

Time Frame

24 hours

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

50 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Signed informed consent prior to any study-related procedures Male or female subjects 18 to 50 years of age inclusive Subject's body mass index (BMI) is ≤ 30 kg/m2 Female subjects of childbearing potential must not be pregnant or lactating with a negative serum human chorionic gonadotropin (HCG) pregnancy test result at Screening, Day -1, or Day 19. Female subjects of childbearing potential and male subjects must use an adequate method of contraception from Screening until completion of the study. Acceptable methods of contraception are barrier methods (male condom, female condom, diaphragm, cervical cap, spermicide, or intrauterine device [IUD]), surgical sterility (documented doctor's report of vasectomy, hysterectomy, and/or bilateral oophorectomy), oral hormonal contraceptives, hormonal IUD, and/or postmenopausal status (defined as at least 1 year without menses as demonstrated by medical history or subject report). Subject is in good health as determined by vital signs, medical history, physical exam, and safety laboratory analyses at Screening and during the study. Exclusion Criteria: Subject has used an investigational product within 30 days prior to enrollment or during the study. Subject has used prescription or non-prescription drugs (including vitamins, minerals, and herbal/plant-derived preparations) within 2 weeks of enrollment (excluding oral hormonal contraceptives, hormonal IUD, hormone replacement therapy, and acetaminophen) unless deemed acceptable by the Investigator in consultation with the Sponsor. Subject has a positive drug and/or alcohol test at Screening, Day -1, or Day 19. Subject has a history of drug or alcohol abuse within 2 years before Screening. Subject is unable to abstain from ingesting alcohol, caffeine, grapefruit or grapefruit juice, pomelo or pomelo juice, or Seville oranges or Seville orange juice for 72 hours prior to dosing and throughout the dosing periods. Concurrent use of substances, including drugs, known to interfere with EPX-100, including moderate or severe inducers or inhibitors of CYP3A4 and CYP2D6. The subject has a clinically significant history of endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major diseases or malignancy. Subject has evidence of any of the following cardiac conduction abnormalities: QTcF interval >430 msec for males and >450 msec for females PR interval ⩾ 200 msec Evidence of second- or third-degree atrioventricular block (AVB) Electrocardiographic evidence of complete left bundle branch block (LBBB), complete right bundle branch block (RBBB), or incomplete LBBB Intraventricular conduction delay with QRS duration >120 msec Heart rate <40 bpm Pathological Q waves (defined as >40 msec or depth >0.4-0.5 mV) Evidence of ventricular pre-excitation.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Hahn-Jun Lee, Ph.D.

Organizational Affiliation

Epygenix Therapeutics, Inc.

Official's Role

Study Director

Facility Information:

Facility Name

TKL Research

City

Fair Lawn

State/Province

New Jersey

ZIP/Postal Code

07410

Country

United States

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

We'll reach out to this number within 24 hrs